Pharmacogenetics of immunosuppressant drugs: A new aspect for individualized therapy

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 5

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Transplant. May 29, 2020; 10(5): 90-103
Published online May 29, 2020. doi: 10.5500/wjt.v10.i5.90

Table 3 Dosing recommendation for tacrolimus based on CYP3A5 phenotype[12]

CYP3A5 phenotype	Implications for tacrolimus pharmacologic measures	Therapeutic recommendations	Classification of recommendation
Extensive metabolizer (CYP3A5 expresser)	Lower dose-adjusted trough concentrations of TAC and decreased chance of achieving target TAC concentrations	Increase starting dose to 1.5-2 times recommended starting dose. Use therapeutic drug monitoring to guide dose adjustments	Strong
Intermediate metabolizer (CYP3A5 expresser)	Lower dose-adjusted trough concentrations of TAC and decreased chance of achieving target TAC concentrations	Increase starting dose to 1.5-2 times recommended starting dose. Use therapeutic drug monitoring to guide dose adjustments	Strong
Poor metabolizer (CYP3A5 non expresser)	Higher dose-adjusted trough concentrations of TAC and increased chance of achieving target TAC concentrations	Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments	Strong

TAC: Tacrolimus.

Citation: Salvadori M, Tsalouchos A. Pharmacogenetics of immunosuppressant drugs: A new aspect for individualized therapy. World J Transplant 2020; 10(5): 90-103
URL: https://www.wjgnet.com/2220-3230/full/v10/i5/90.htm
DOI: https://dx.doi.org/10.5500/wjt.v10.i5.90

Salvadori M, Tsalouchos A. Pharmacogenetics of immunosuppressant drugs: A new aspect for individualized therapy. World J Transplant 2020; 10(5): 90-103 [PMID: 32864355 DOI: 10.5500/wjt.v10.i5.90]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.